101
|
Posttranslational modifications of cardiac troponin T: An overview. J Mol Cell Cardiol 2013; 63:47-56. [DOI: 10.1016/j.yjmcc.2013.07.004] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Revised: 06/18/2013] [Accepted: 07/08/2013] [Indexed: 12/22/2022]
|
102
|
Kirk JA, Zhang P, Murphy AM, Van Eyk JE. Troponin I alterations detected by multiple-reaction monitoring: how might this impact the study of heart failure? Expert Rev Proteomics 2013; 10:5-8. [PMID: 23414352 DOI: 10.1586/epr.12.77] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
103
|
Taube D, Xu J, Yang XP, Undrovinas A, Peterson E, Harding P. Fractalkine depresses cardiomyocyte contractility. PLoS One 2013; 8:e69832. [PMID: 23936109 PMCID: PMC3728327 DOI: 10.1371/journal.pone.0069832] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Accepted: 06/14/2013] [Indexed: 12/02/2022] Open
Abstract
Background Our laboratory reported that male mice with cardiomyocyte-selective knockout of the prostaglandin E2 EP4 receptor sub-type (EP4 KO) exhibit reduced cardiac function. Gene array on left ventricles (LV) showed increased fractalkine, a chemokine implicated in heart failure. We therefore hypothesized that fractalkine is regulated by PGE2 and contributes to depressed contractility via alterations in intracellular calcium. Methods Fractalkine was measured in LV of 28–32 week old male EP4 KO and wild type controls (WT) by ELISA and the effect of PGE2 on fractalkine secretion was measured in cultured neonatal cardiomyocytes and fibroblasts. The effect of fractalkine on contractility and intracellular calcium was determined in Fura-2 AM-loaded, electrical field-paced cardiomyocytes. Cardiomyocytes (AVM) from male C57Bl/6 mice were treated with fractalkine and responses measured under basal conditions and after isoproterenol (Iso) stimulation. Results LV fractalkine was increased in EP4 KO mice but surprisingly, PGE2 regulated fractalkine secretion only in fibroblasts. Fractalkine treatment of AVM decreased both the speed of contraction and relaxation under basal conditions and after Iso stimulation. Despite reducing contractility after Iso stimulation, fractalkine increased the Ca2+ transient amplitude but decreased phosphorylation of cardiac troponin I, suggesting direct effects on the contractile machinery. Conclusions Fractalkine depresses myocyte contractility by mechanisms downstream of intracellular calcium.
Collapse
Affiliation(s)
- David Taube
- Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Michigan, United States of America
| | - Jiang Xu
- Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Michigan, United States of America
| | - Xiao-Ping Yang
- Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Michigan, United States of America
| | - Albertas Undrovinas
- Cardiovascular Research Division, Henry Ford Hospital, Detroit, Michigan, United States of America
| | - Edward Peterson
- Department of Internal Medicine and Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan, United States of America
| | - Pamela Harding
- Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Michigan, United States of America
- * E-mail:
| |
Collapse
|
104
|
Li A, Estigoy C, Raftery M, Cameron D, Odeberg J, Pontén F, Lal S, Dos Remedios CG. Heart research advances using database search engines, Human Protein Atlas and the Sydney Heart Bank. Heart Lung Circ 2013; 22:819-26. [PMID: 23856366 DOI: 10.1016/j.hlc.2013.06.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Revised: 06/07/2013] [Accepted: 06/11/2013] [Indexed: 10/26/2022]
Abstract
This Methodological Review is intended as a guide for research students who may have just discovered a human "novel" cardiac protein, but it may also help hard-pressed reviewers of journal submissions on a "novel" protein reported in an animal model of human heart failure. Whether you are an expert or not, you may know little or nothing about this particular protein of interest. In this review we provide a strategic guide on how to proceed. We ask: How do you discover what has been published (even in an abstract or research report) about this protein? Everyone knows how to undertake literature searches using PubMed and Medline but these are usually encyclopaedic, often producing long lists of papers, most of which are either irrelevant or only vaguely relevant to your query. Relatively few will be aware of more advanced search engines such as Google Scholar and even fewer will know about Quertle. Next, we provide a strategy for discovering if your "novel" protein is expressed in the normal, healthy human heart, and if it is, we show you how to investigate its subcellular location. This can usually be achieved by visiting the website "Human Protein Atlas" without doing a single experiment. Finally, we provide a pathway to discovering if your protein of interest changes its expression level with heart failure/disease or with ageing.
Collapse
Affiliation(s)
- Amy Li
- Discipline of Anatomy & Histology, Bosch Institute, University of Sydney, Sydney 2006, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
105
|
Bleijerveld OB, Zhang YN, Beldar S, Hoefer IE, Sze SK, Pasterkamp G, de Kleijn DPV. Proteomics of plaques and novel sources of potential biomarkers for atherosclerosis. Proteomics Clin Appl 2013; 7:490-503. [DOI: 10.1002/prca.201200119] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2012] [Revised: 03/07/2013] [Accepted: 03/30/2013] [Indexed: 12/14/2022]
Affiliation(s)
- Onno B. Bleijerveld
- Laboratory of Experimental Cardiology; University Medical Center Utrecht; Utrecht the Netherlands
| | - Ya-Nan Zhang
- Surgery & Cardiovascular Research Institute; National University (NUS) & National University Hospital (NUH); Singapore
| | - Serap Beldar
- School of Biological Sciences; Nanyang Technological University; Singapore
| | - Imo E. Hoefer
- Laboratory of Experimental Cardiology; University Medical Center Utrecht; Utrecht the Netherlands
| | - Siu K. Sze
- School of Biological Sciences; Nanyang Technological University; Singapore
| | - Gerard Pasterkamp
- Laboratory of Experimental Cardiology; University Medical Center Utrecht; Utrecht the Netherlands
| | - Dominique P. V. de Kleijn
- Laboratory of Experimental Cardiology; University Medical Center Utrecht; Utrecht the Netherlands
- Surgery & Cardiovascular Research Institute; National University (NUS) & National University Hospital (NUH); Singapore
- Interuniversity Cardiology Institute of the Netherlands; Utrecht the Netherlands
| |
Collapse
|
106
|
Liu X, Jin Z, O’Brien R, Bathon J, Dietz HC, Grote E, Van Eyk JE. Constrained selected reaction monitoring: quantification of selected post-translational modifications and protein isoforms. Methods 2013; 61:304-12. [PMID: 23523700 PMCID: PMC3990191 DOI: 10.1016/j.ymeth.2013.03.006] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2012] [Revised: 03/02/2013] [Accepted: 03/06/2013] [Indexed: 10/27/2022] Open
Abstract
Selected reaction monitoring (SRM) is a mass spectrometry method that can target signature peptides to provide for the detection and quantitation of specific proteins in complex biological samples. When quantifying a protein, multiple peptides are generated using a specific protease such as trypsin, thereby allowing a choice of signature peptides with robust signals. In contrast, signature peptide selection can be constrained when the goal is to monitor a specific post-translational modification (PTM) or protein isoform, as the signature peptide must include the amino acid residue(s) of PTM attachment or sequence variation. This can force the selection of a signature peptide with a weak SRM response or one that is confounded by high background. In this article, we discuss steps that can be optimized to maximize peptide selection and assay performance of constrained SRM assays, including tuning instrument parameters, fragmenting product ions, using a different protease, and enriching the sample. Examples are provided for phosphorylated or citrullinated peptides and protein isoforms.
Collapse
Affiliation(s)
- Xiaoqian Liu
- Department of Medicine, Jonhns Hopkins University, New York, NY
| | - Zhicheng Jin
- Department of Medicine, Jonhns Hopkins University, New York, NY
| | - Richard O’Brien
- Department of Neurology, Johns Hopkins Bayview Medical Center, New York, NY
| | - Joan Bathon
- Department of Medicine, Columbia Medical School, New York, NY
| | - Harry C. Dietz
- Department of Pediatrics, Johns Hopkins University, Baltimore MD
| | - Eric Grote
- Department of Medicine, Jonhns Hopkins University, New York, NY
| | - Jennifer E. Van Eyk
- Department of Medicine, Jonhns Hopkins University, New York, NY
- Department of Biological Chemistry and Biomedical Engineering, Johns Hopkins University, Baltimore MD
| |
Collapse
|
107
|
Current World Literature. Curr Opin Cardiol 2013; 28:369-79. [DOI: 10.1097/hco.0b013e328360f5be] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
108
|
Sequeira V, Wijnker PJM, Nijenkamp LLAM, Kuster DWD, Najafi A, Witjas-Paalberends ER, Regan JA, Boontje N, Ten Cate FJ, Germans T, Carrier L, Sadayappan S, van Slegtenhorst MA, Zaremba R, Foster DB, Murphy AM, Poggesi C, Dos Remedios C, Stienen GJM, Ho CY, Michels M, van der Velden J. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res 2013; 112:1491-505. [PMID: 23508784 DOI: 10.1161/circresaha.111.300436] [Citation(s) in RCA: 164] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
RATIONALE High-myofilament Ca(2+) sensitivity has been proposed as a trigger of disease pathogenesis in familial hypertrophic cardiomyopathy (HCM) on the basis of in vitro and transgenic mice studies. However, myofilament Ca(2+) sensitivity depends on protein phosphorylation and muscle length, and at present, data in humans are scarce. OBJECTIVE To investigate whether high myofilament Ca(2+) sensitivity and perturbed length-dependent activation are characteristics for human HCM with mutations in thick and thin filament proteins. METHODS AND RESULTS Cardiac samples from patients with HCM harboring mutations in genes encoding thick (MYH7, MYBPC3) and thin (TNNT2, TNNI3, TPM1) filament proteins were compared with sarcomere mutation-negative HCM and nonfailing donors. Cardiomyocyte force measurements showed higher myofilament Ca(2+) sensitivity in all HCM samples and low phosphorylation of protein kinase A (PKA) targets compared with donors. After exogenous PKA treatment, myofilament Ca(2+) sensitivity was similar (MYBPC3mut, TPM1mut, sarcomere mutation-negative HCM), higher (MYH7mut, TNNT2mut), or even significantly lower (TNNI3mut) compared with donors. Length-dependent activation was significantly smaller in all HCM than in donor samples. PKA treatment increased phosphorylation of PKA-targets in HCM myocardium and normalized length-dependent activation to donor values in sarcomere mutation-negative HCM and HCM with truncating MYBPC3 mutations but not in HCM with missense mutations. Replacement of mutant by wild-type troponin in TNNT2mut and TNNI3mut corrected length-dependent activation to donor values. CONCLUSIONS High-myofilament Ca(2+) sensitivity is a common characteristic of human HCM and partly reflects hypophosphorylation of PKA targets compared with donors. Length-dependent sarcomere activation is perturbed by missense mutations, possibly via posttranslational modifications other than PKA hypophosphorylation or altered protein-protein interactions, and represents a common pathomechanism in HCM.
Collapse
Affiliation(s)
- Vasco Sequeira
- Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, the Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
109
|
Abstract
We focus here on the modulation of thin filament activity by cardiac troponin I phosphorylation as an integral and adaptive mechanism in cardiac homeostasis and as a mechanism vulnerable to maladaptive response to stress. We discuss a current concept of cardiac troponin I function in the A-band region of the sarcomere and potential signaling to cardiac troponin I in a network involving the ends of the thin filaments at the Z-disk and the M-band regions. The cardiac sarcomere represents a remarkable set of interacting proteins that functions not only as a molecular machine generating the heartbeat but also as a hub of signaling. We review how phosphorylation signaling to cardiac troponin I is integrated, with parallel signals controlling excitation-contraction coupling, hypertrophy, and metabolism.
Collapse
Affiliation(s)
- R John Solaro
- Department of Physiology and Biophysics and Center for Cardiovascular Research, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA.
| | | | | |
Collapse
|
110
|
Ryan JJ, Musunuru K, Prakash SK. Top advances in functional genomics and translational biology for 2012. CIRCULATION. CARDIOVASCULAR GENETICS 2013; 6:132-134. [PMID: 23424257 DOI: 10.1161/circgenetics.111.000043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Affiliation(s)
- John J Ryan
- Early Career Committee of the American Heart Association, Functional Genomics and Translational Biology Council, Dallas, TX, USA.
| | | | | |
Collapse
|
111
|
A kinase interacting protein (AKIP1) is a key regulator of cardiac stress. Proc Natl Acad Sci U S A 2013; 110:E387-96. [PMID: 23319652 DOI: 10.1073/pnas.1221670110] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
cAMP-dependent protein kinase (PKA) regulates a myriad of functions in the heart, including cardiac contractility, myocardial metabolism,and gene expression. However, a molecular integrator of the PKA response in the heart is unknown. Here, we show that the PKA adaptor A-kinase interacting protein 1 (AKIP1) is up-regulated in cardiac myocytes in response to oxidant stress. Mice with cardiac gene transfer of AKIP1 have enhanced protection to ischemic stress. We hypothesized that this adaptation to stress was mitochondrial dependent. AKIP1 interacted with the mitochondrial localized apoptosis inducing factor (AIF) under both normal and oxidant stress. When cardiac myocytes or whole hearts are exposed to oxidant and ischemic stress, levels of both AKIP1 and AIF were enhanced. AKIP1 is preferentially localized to interfibrillary mitochondria and up-regulated in this cardiac mitochondrial subpopulation on ischemic injury. Mitochondria isolated from AKIP1 gene transferred hearts showed increased mitochondrial localization of AKIP1, decreased reactive oxygen species generation, enhanced calcium tolerance, decreased mitochondrial cytochrome C release,and enhance phosphorylation of mitochondrial PKA substrates on ischemic stress. These observations highlight AKIP1 as a critical molecular regulator and a therapeutic control point for stress adaptation in the heart.
Collapse
|
112
|
Myofilament incorporation and contractile function after gene transfer of cardiac troponin I Ser43/45Ala. Arch Biochem Biophys 2013; 535:49-55. [PMID: 23318976 DOI: 10.1016/j.abb.2012.12.021] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2012] [Revised: 12/21/2012] [Accepted: 12/23/2012] [Indexed: 11/23/2022]
Abstract
Phosphorylation of cardiac troponin I serines 43/45 (cTnISer43/45) by protein kinase C (PKC) is associated with cardiac dysfunction and yet there is disagreement about the role this cluster plays in modulating contractile performance. The present study evaluates the impact of phospho-null Ala substitutions at Ser43/45 (cTnISer43/45Ala) on contractile performance in intact myocytes. Viral-based gene transfer of cardiac troponin I (cTnI) or cTnISer43/45Ala resulted in time-dependent increases in expression, with 70-80% of endogenous cTnI replaced within 4days. Western analysis of intact and permeabilized myocytes along with immunohistochemistry showed each exogenous cTnI was incorporated into the sarcomere of myocytes. In contractile function studies, there were no differences in shortening and re-lengthening for cTnI and cTnISer43/45Ala-expressing myocytes 2days after gene transfer. However, more extensive replacement with cTnISer43/45Ala after 4days diminished peak shortening amplitude and accelerated re-lengthening measured as the time to 50% re-lengthening (TTR50%). A decrease in myofilament Ca(2+) sensitivity of tension also was observed in permeabilized myocytes expressing cTnISer43/45Ala and is consistent with accelerated re-lengthening observed in intact myocytes under basal conditions. Phosphorylation of cTnI Ser23/24 and the Ca(2+) transient were not changed in these myocytes. These results demonstrate extensive sarcomere expression of cTnISer43/45Ala directly modulates myofilament function under basal conditions. In further work, the accelerated re-lengthening observed in control or cTnI-expressing myocytes treated with the PKC agonist, endothelin-1 (ET, 10nM) was slowed in myocytes expressing cTnISer43/45Ala. This outcome may indicate Ser43/45 is targeted for phosphorylation by ET-activated PKC and/or influences transduction of this agonist-activated response.
Collapse
|
113
|
Affiliation(s)
- Christopher I. Murray
- Department of Biological Chemistry, Division of Cardiology and Biomedical Engineering, Johns Hopkins University, Baltimore MD
| | - Jennifer E. Van Eyk
- Department of Biological Chemistry, Division of Cardiology and Biomedical Engineering, Johns Hopkins University, Baltimore MD
- Department of Medicine, Division of Cardiology and Biomedical Engineering, Johns Hopkins University, Baltimore MD
| |
Collapse
|
114
|
Cordwell SJ, White MY. Targeted Proteomics for Determining Phosphorylation Site-Specific Associations in Cardiovascular Disease. Circulation 2012; 126:1803-7. [DOI: 10.1161/circulationaha.112.136507] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Stuart J. Cordwell
- From the School of Molecular Bioscience (S.J.C., M.Y.W.), and Discipline of Pathology, School of Medical Sciences (S.J.C.), The University of Sydney, New South Wales, Australia
| | - Melanie Y. White
- From the School of Molecular Bioscience (S.J.C., M.Y.W.), and Discipline of Pathology, School of Medical Sciences (S.J.C.), The University of Sydney, New South Wales, Australia
| |
Collapse
|